Vaccine Breakthrough Infections and SARS-CoV-2 Variants

Nature Research Intelligence published a summary on vaccine breakthrough infections and SARS-CoV-2 variants. The summary said breakthrough infections occur when individuals contract the virus despite completing an authorised immunisation schedule. It said key drivers include waning immunity, host factors such as age and comorbidity, and the emergence of variants of concern with spike-protein alterations. The summary said most breakthrough cases remain mild or asymptomatic but can sustain transmission and challenge herd immunity. It cited a cohort study during a Delta variant surge that found approximately one quarter of fully vaccinated healthcare workers developed serological evidence of infection within two months of their second dose. The summary said the study found ChAdOx1-nCoV19 maintains high efficacy for clinical endpoints but is insufficient to fully interrupt transmission in high-exposure settings. It cited research in Bangladesh during the Omicron wave showing over half of hospital-based healthcare workers exhibited seropositivity for nucleocapsid antibodies after vaccination, with overweight and obesity as independent risk factors. The summary said booster coverage was associated with a modest reduction in serological markers of infection. It cited data from western India where breakthrough cases during the Delta-driven second wave accounted for nearly 17% of infections. The summary said research in Vietnam found Delta variant infections 7-8 weeks post-immunisation with high viral loads irrespective of symptomatology.